Online inquiry

IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12755MR)

This product GTTS-WQ12755MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets NOTCH1 gene. The antibody can be applied in Lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_017617.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4851
UniProt ID P46531
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12755MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4935MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ5627MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDP870
GTTS-WQ3064MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ6623MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ7276MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FP3 protein
GTTS-WQ14029MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aLAG367
GTTS-WQ501MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 47H4
GTTS-WQ3808MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BB-10901
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW